AKBA Stock Risk & Deep Value Analysis
Akebia Therapeutics Inc
Healthcare • Drug Manufacturers - Specialty & Generic
DVR Score
out of 10
The Bottom Line on AKBA
We analyzed Akebia Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran AKBA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
📈AKBA Performance Overview3yr weekly
Unlock AKBA Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
AKBA Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
About Akebia Therapeutics Inc (AKBA)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Market Cap Category
small
Market Cap
$737.10M
AKBA Deep Value Analysis
AKBA Red Flags & Warning Signs
Premium- ⚠
Continued cash burn exceeding expectations
- ⚠
Further dilution through equity offerings
- ⚠
Failure to achieve sales targets for existing products
- ⚠
Increased competition in existing markets
- ⚠
Debt covenant breaches or refinancing challenges
Unlock AKBA Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
AKBA Financial Health Metrics
Market Cap
$737.10M
AKBA Competitive Moat Analysis
PremiumMoat Rating
None
Moat Trend
Eroding
Moat Sources
2 Identified
Akebia's existing products face significant competition and generic threats in the long term. The regulatory setback for vadadustat in the US severely impaired any potential wider moat from that asset. Without a new, differentiated asset or market capture, the company's competitive advantages are not durable.
AKBA Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
AKBA Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Expected mid-March 2026)
- •Updates on Auryxia commercial performance
- •Updates on Vafseo ex-US market penetration
Medium-Term (6-18 months)
- •Potential new business development or partnership announcements (highly speculative for growth)
- •Cost reduction initiatives yielding significant results
Long-Term (18+ months)
- •Acquisition of a transformative new pipeline asset (highly speculative and not currently indicated as a 10x driver)
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
AKBA Bull Case: What Could Go Right
- ✓
Announcement of a new, game-changing pipeline asset acquisition or in-licensing agreement.
- ✓
Sustained quarter-over-quarter profitability and significant positive free cash flow.
- ✓
Major debt restructuring that significantly reduces financial leverage and dilution risk.
Bull Case Analysis
See what could go right with Premium
Never miss a move on AKBA
Create a free account to set price alerts and get notified on Telegram when AKBA hits your targets.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for Akebia Therapeutics Inc (AKBA)?
As of March 3, 2026, Akebia Therapeutics Inc has a DVR Score of 1.0 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Akebia Therapeutics Inc?
Akebia Therapeutics Inc's market capitalization is approximately $737.1M. The company operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.
What ticker symbol does Akebia Therapeutics Inc use?
AKBA is the ticker symbol for Akebia Therapeutics Inc. The company trades on the NCM.
What is the risk level for AKBA stock?
Our analysis rates Akebia Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the AKBA DVR analysis updated?
Our AI-powered analysis of Akebia Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 3, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.